BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Update

BeiGene, Ltd. (NASDAQ:BGNE) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,330,000 shares, an increase of 33.1% from the November 15th total of 999,400 shares. Based on an average daily volume of 367,900 shares, the short-interest ratio is presently 3.6 days.

BeiGene Price Performance

Shares of BGNE traded down $0.92 on Friday, reaching $179.35. The stock had a trading volume of 368,585 shares, compared to its average volume of 281,770. BeiGene has a twelve month low of $126.97 and a twelve month high of $248.16. The firm has a market capitalization of $17.47 billion, a PE ratio of -21.77 and a beta of 0.57. The firm has a 50-day moving average of $207.23 and a 200 day moving average of $186.66. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period last year, the company posted $2.01 EPS. Sell-side analysts expect that BeiGene will post -5.64 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. JPMorgan Chase & Co. raised their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 22nd. JMP Securities began coverage on shares of BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and set a $300.00 target price on shares of BeiGene in a research report on Tuesday, December 3rd. TD Cowen increased their target price on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.69.

Insider Buying and Selling

In other BeiGene news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the completion of the sale, the director now directly owns 791,493 shares of the company’s stock, valued at approximately $148,222,894.11. This trade represents a 56.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. Insiders sold a total of 1,136,622 shares of company stock worth $213,521,417 in the last 90 days. Company insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Large investors have recently added to or reduced their stakes in the business. Raymond James & Associates grew its position in shares of BeiGene by 0.4% in the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock valued at $3,035,000 after purchasing an additional 76 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in BeiGene by 21.7% during the 2nd quarter. EFG Asset Management North America Corp. now owns 17,780 shares of the company’s stock valued at $2,540,000 after buying an additional 3,170 shares during the last quarter. Van ECK Associates Corp grew its holdings in BeiGene by 8.9% during the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after buying an additional 7,816 shares during the last quarter. Fiera Capital Corp increased its position in BeiGene by 45.9% during the second quarter. Fiera Capital Corp now owns 3,736 shares of the company’s stock worth $533,000 after buying an additional 1,176 shares in the last quarter. Finally, TD Asset Management Inc raised its holdings in shares of BeiGene by 1.4% in the second quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock worth $16,318,000 after acquiring an additional 1,599 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.